peptuity.
WhatsApp

home / compounds / Retatrutide

Well researchedMetabolic & fat loss

Retatrutide

LY3437943

Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.

01

What it is

An investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

02

What it does

Adding glucagon-receptor activity to the incretin pathways is thought to increase energy expenditure alongside appetite suppression.

Does it work?

Phase 2 results reported average weight reduction higher than any previously trialled agent, which is why interest is intense. It remains investigational — not approved by the SFDA, FDA or EMA — and long-term safety data is not yet complete.

03

Claims vs data

Each marketing claim, tagged by what the evidence actually supports.

Largest weight loss of any trialled agent to datepartially true
Approved and availableoverreach
04

Reference figures

Quoted from published reference material. These are not Peptuity recommendations.

Vial10 mg
Diluent2 ml
Listed dose0.5–1 mg
Units / 1 ml10–20

Open in the calculator — prefilled →

05

The evidence, counted

Live counts from Europe PMC and ClinicalTrials.gov.

Publications 730
Randomised trials 15
Clinical trials 16
Registered studies 33

730 publications indexed, but only 15 randomised controlled trials and 33 registered interventional studies. Human evidence exists but is thin.

query: "Retatrutide" · checked 2026-08-07

Most-cited literature

Regulatory status

Formal, dated regulatory actions.

WADA — Prohibited List 2026

Prohibited in sport — WADA S0 (substance without any health-authority approval)

source →

06

Common questions

When will retatrutide be approved?

Unknown. Phase 3 trials are ongoing; until they read out and regulators review them, any date is speculation.

Why is it graded below the approved GLP-1 drugs?

Its headline results are phase 2. Impressive, but smaller and shorter than the phase 3 programmes behind semaglutide and tirzepatide, with long-term safety still incomplete.

Is the vialled retatrutide being sold online the trial drug?

No vialled product sold outside the trial programme is verified. The trial evidence attaches to the manufacturer’s controlled material, not to grey-market copies.

07

Related compounds

FDA approved

Tirzepatide

Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.
FDA approved

Semaglutide

GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.
Emerging

Cagrilintide

Amylin analogue, mainly studied combined with semaglutide.

Research use only

All content on Peptuity is provided for research and educational purposes only. Peptuity does not sell, distribute, or facilitate the purchase of any compound, does not provide medical advice, and makes no claims regarding safety or efficacy. Most compounds discussed are not approved for human use by the SFDA or FDA. Always consult a qualified physician.

Ask a question